Purchase this article with an account.
C. Lai, W. Wu, S. Chen, M. Sun, T. Chen, R. Tsai, Y. Tsao; Prevention of Experimental Choroidal Neovascularization by Intravitreal Injection of Recombinant Adeno-Associated Virus (rAAV) Vector Expressing Mouse Angiostatin . Invest. Ophthalmol. Vis. Sci. 2003;44(13):581.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To prevent experimental choroidal neovascularization (CNV) in a rat model with intravitreal injection of recombinant adeno-associated virus (rAAV) vector expressing mouse angiostatin. Methods: rAAV-angiostatin and control virus rAAV-lacZ were delivered in vivo by intravitreal injection on Brown Norway rats and the delivery was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR). CNV was produced by krypton laser photocoagulation 7 days after viral vector injection and was evaluated by fluorescein-dextran (FITC) angiography and histology. Apoptosis in retina was analyzed using terminal deoxynucleotidyl transferase-mediated biotin-deoxyuridine triphosphate nick and labeling assay (TUNEL). Inflammation in retina was investigated by immunohistochemistry using antibodies recognizing lymphocytes. Results: rAAV-angiostatin intravitreal injection led to sustained expression of angiostatin gene in retinal tissue. FITC angiography analysis and histology revealed significant reduction of the average sizes of CNV lesion in rAAV-angiostatin injected eyes when compared with rAAV-lacZ injected eyes at 14 and days after. As to the adverse effects, rAAV-angiostatin injection did not cause inflammation or apoptosis of cells in retina and choroid. Conclusions: In this study, we confirmed intravitral injection of rAAV-angiostatin could significantly reduce the sizes of CNV lesion. The results showed the feasibility of intravitreal injection of rAAV-angiostatin as treatment of experimental CNV.
This PDF is available to Subscribers Only